SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark Life Sciences reports 33% fall in Q4 net profit

25 Apr 2024 Evaluate

Glenmark Life Sciences has reported results for fourth quarter (Q4) and year ended March 31, 2024.

The company has reported 33.08% fall in its net profit at Rs 97.94 crore for the quarter under review as compared to Rs 146.36 crore for the same quarter in the previous year. Total income of the company decreased by 13.53% at Rs 539.73 crore for Q4FY24 as compared Rs 624.16 crore for the corresponding quarter previous year. 

For the year ended March 31, 2024, the company has reported marginal rise of 0.84% in its net profit at Rs 470.89 crore as compared to Rs 466.96 crore for the previous year. Total income of the company increased by 4.80% at Rs 2295.26 crore for year under review as compared to Rs 2190.18 crore for year ended March 31, 2023.

Alivus Life Sciences Share Price

1050.35 -10.40 (-0.98%)
24-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1619.95
Dr. Reddys Lab 1315.85
Cipla 1294.75
Zydus Lifesciences 927.15
Lupin 2296.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×